Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Vera Therapeutics, Inc. ( VERA ) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 5:35 PM EDT Company Participants Marshall Fordyce - Founder, President, CEO & Director Presentation Unknown Analyst Great. Good afternoon, everybody. Thanks for sticking around for our last fireside today. We're really pleased to have Vera with us. I'm going to let Marshall make some introductory comments, and then we'll jump into Q&A. Over to you, Marshall. Thanks. Marshall Fordyce Founder, President, CEO & Director Matthew, thanks for having us and me at your conference. Great to have an interview with you today. I'm Marshall Fordyce, I'm the Founder and CEO of Vera Therapeutics. Great day for us today and for patients. Today, we shared the final efficacy analysis from our pivotal Phase III trial, showing outstanding efficacy by eGFR and by kidney composite endpoint. It was an important update for the field and for Vera as well as an indication of how launch is going. So we shared that so far, about 10 weeks into our first commercial launch, we have over 350 patient start forms or roughly prescriptions as an early indication of demand. So 2 important updates for the company, great activity happening now and in the coming time, here we are in September. The data that we toplined today are being submitted or have been submitted both for presentation and publication. It would be great if we could get that done at the next month's major kidney conference, which is called ASN, where we would hope to have an opportunity to present these data in a more fulsome way to the academic world. And in conjunction with that, We, of course, are pursuing an sBLA in Q4 to target full approval with these top line data and more for mid-2027. So a fantastic moment for us